Redmond, William

Graduate Student

Positions

2016 - Director, Immune Monitoring Laboratory, Earle A. Chiles Research Institute
2013 - Faculty Member Adjunct, Oregon Health & Science University

Websites

Doctoral Dissertation

Publications
Background
Contact
Identity
View All

recent publications

All Publications

PubMed Display for Export

Publications without PubMed PMIDs

academic article
- Conrad, V. K., Dubay, C. J., Malek, M., Brinkman, R. R., Koguchi, Y., Redmond, W. L. Implementation and validation of an automated flow cytometry analysis pipeline for human immune profiling Cytometry Part A 2019 95A:183-191 DOI:10.1002/cyto.a.23664 PMID:30570217
- Emerson, D. A., Redmond, W. L. Overcoming tumor-induced immune suppression: from relieving inhibition to providing costimulation with T cell agonists Biodrugs 2018 32:221-231 DOI:10.1007/s40259-018-0277-2 PMID:29637478
- Wrangle, J. M., Velcheti, V., Patel, M. R., Garrett-Mayer, E., Hill, E. G., Ravenel, J. G., Miller, J. S., Farhad, M., Anderton, K., Lindsey, K., Taffaro-Neskey, M., Sherman, C., et al. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial Lancet Oncology 2018 19:694-704 DOI:10.1016/s1470-2045(18)30148-7 PMID:29628312
- Farhad, M., Rolig, A. S., Redmond, W. L. The role of Galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironment Oncoimmunology 2018 7 DOI:10.1080/2162402x.2018.1434467 PMID:29872573 PMCID:PMC5980349
- Emens, L. A., Ascierto, P. A., Darcy, P. K., Demaria, S., Eggermont, A. M. M., Redmond, W. L., Seliger, B., Marincola, F. M. Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape European Journal of Cancer 2017 81:116-129 DOI:10.1016/j.ejca.2017.01.035 PMID:28623775
- Graff, J. N., Alumkal, J. J., Drake, C. G., Thomas, G. V., Redmond, W. L., Farhad, M., Cetnar, J. P., Ey, F. S., Bergan, R. C., Slottke, R., Beer, T. M. Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer Oncotarget 2016 7:52810-52817 DOI:10.18632/oncotarget.10547 PMID:27429197 PMCID:PMC5288150
- McNamara, M. J., Hilgart-Martiszus, I., Echenique, D. M. B., Linch, S. N., Kasiewicz, M. J., Redmond, W. L. Interferon-γ production by peripheral lymphocytes predicts survival of tumor-bearing mice receiving dual PD-1/CTLA-4 blockade Cancer Immunology Research 2016 4:650-657 DOI:10.1158/2326-6066.cir-16-0022 PMID:27262113
- Linch, S. N., Redmond, W. L. How do I steer this thing? Using dendritic cell targeted vaccination to more effectively guide the antitumor immune response with combination immunotherapy Journal for Immunotherapy of Cancer 2016 4 DOI:10.1186/s40425-016-0135-z PMID:27330804 PMCID:PMC4915175
- Linch, S. N., Kasiewicz, M. J., McNamara, M. J., Hilgart-Martiszus, I. F., Farhad, M., Redmond, W. L. Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice Proceedings of the National Academy of Sciences of the United States of America 2016 113:E319-E327 DOI:10.1073/pnas.1510518113 PMID:26729864 PMCID:PMC4725491
- Redmond, W. L., Linch, S. N. Combinatorial immunotherapeutic approaches to restore the function of anergic tumor-reactive cytotoxic CD8(+) T cells Human Vaccines & Immunotherapeutics 2016 12:2519-2522 DOI:10.1080/21645515.2016.1193277 PMID:27459422 PMCID:PMC5084978
- Linch, S. N., McNamara, M. J., Redmond, W. L. OX40 agonists and combination immunotherapy: putting the pedal to the metal Frontiers in Oncology 2015 5 DOI:10.3389/fonc.2015.00034 PMID:25763356 PMCID:PMC4329814
- Redmond, W. L., Linch, S. N., Kasiewicz, M. J. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity Cancer Immunology Research 2014 2:142-153 DOI:10.1158/2326-6066.cir-13-0031-t PMID:24778278 PMCID:PMC4007342
- Linch, S. N., Redmond, W. L. Combined OX40 ligation plus CTLA-4 blockade: more than the sum of its parts Oncoimmunology 2014 3 DOI:10.4161/onci.28245 PMID:25050194 PMCID:PMC4091104
- McNamara, M. J., Kasiewicz, M. J., Linch, S. N., Dubay, C., Redmond, W. L. Common gamma chain (gammac) cytokines differentially potentiate TNFR family signaling in antigen-activated CD8(+) T cells Journal for Immunotherapy of Cancer 2014 2 DOI:10.1186/s40425-014-0028-y PMID:25411639 PMCID:PMC4236884
- Crittenden, M. R., Savage, T., Cottam, B., Bahjat, K. S., Redmond, W. L., Bambina, S., Kasiewicz, M., Newell, P., Jackson, A. M., Gough, M. J. The peripheral myeloid expansion driven by murine cancer progression is reversed by radiation therapy of the tumor PLoS One 2013 8 DOI:10.1371/journal.pone.0069527 PMID:23936036 PMCID:PMC3723876
- Redmond, W. L., Triplett, T., Floyd, K., Weinberg, A. D. Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression PLoS One 2012 7 DOI:10.1371/journal.pone.0034467 PMID:22496812 PMCID:PMC3319580
- Gough, M. J., Crittenden, M. R., Sarff, M., Pang, P., Seung, S. K., Vetto, J. T., Hu, H. M., Redmond, W. L., Holland, J., Weinberg, A. D. Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice Journal of Immunotherapy 2010 33:798-809 DOI:10.1097/CJI.0b013e3181ee7095 PMID:20842057 PMCID:PMC3563298
- Jensen, S. M., Maston, L. D., Gough, M. I., Ruby, C. E., Redmond, W. L., Crittenden, M., Li, Y., Puri, S., Poehlein, C. H., Morris, N., Kovacsovics-Bankowski, M., Moudgil, T., et al. Signaling through OX40 enhances antitumor immunity Seminars in Oncology 2010 37:524-532 DOI:10.1053/j.seminoncol.2010.09.013 PMID:21074068 PMCID:PMC2997672
- Redmond, W. L., Gough, M. J., Weinberg, A. D. Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo European Journal of Immunology 2009 39:2184-2194 DOI:10.1002/eji.200939348 PMID:19672905 PMCID:PMC3509800
- Redmond, W. L., Ruby, C. E., Weinbergr, A. D. The role of OX40-mediated co-stimulation in T-cell activation and survival Critical Reviews in Immunology 2009 29:187-201 PMID:19538134 PMCID:PMC3180959
- Gough, M. J., Ruby, C. E., Redmond, W. L., Dhungel, B., Brown, A., Weinberg, A. D. OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor Cancer Research 2008 68:5206-5215 DOI:10.1158/0008-5472.can-07-6484 PMID:18593921
- Redmond, W. L., Wei, C. H., Kreuwel, H. T. C., Sherman, L. A. The apoptotic pathway contributing to the deletion of naive CD8 T cells during the induction of peripheral tolerance to a cross-presented self-antigen Journal of Immunology 2008 180:5275-5282 PMID:18390708
- Redmond, W. L., Gough, M. J., Charbonneau, B., Ratliff, T. L., Weinberg, A. D. Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist Journal of Immunology 2007 179:7244-7253 PMID:18025166
- Ruby, C. E., Redmond, W. L., Haley, D., Weinberg, A. D. Anti-OX40 stimulation in vivo enhances CD8(+) memory T cell survival and significantly increases recall responses European Journal of Immunology 2007 37:157-166 DOI:10.1002/eji.200636428 PMID:17183611
- Redmond, W. L., Weinberg, A. D. Targeting OX40 and OX40L for the treatment of autoimmunity and cancer Critical Reviews in Immunology 2007 27:415-436 PMID:18197805
- Martinez, X., Kreuwel, H. T. C., Redmond, W. L., Trenney, R., Hunter, K., Rosen, H., Sarvetnick, N., Wicker, L. S., Sherman, L. A. CD8+ T cell tolerance in nonobese diabetic mice is restored by insulin-dependent diabetes resistance alleles Journal of Immunology 2005 175:1677-1685 PMID:16034108
- Redmond, W. L., Sherman, L. A. Peripheral tolerance of CD8 T lymphocytes Immunity 2005 22:275-284 DOI:10.1016/j.immuni.2005.01.010 PMID:15780985
- Redmond, W. L., Marincek, B. C., Sherman, L. A. Distinct requirements for deletion versus anergy during CD8 T cell peripheral tolerance in vivo Journal of Immunology 2005 174:2046-2053 PMID:15699134
- Yadav, D., Judkowski, V., Flodstrom-Tullberg, M., Sterling, L., Redmond, W. L., Sherman, L., Sarvetnick, N. B7-2 (CD86) controls the priming of autoreactive CD4 T cell response against pancreatic islets Journal of Immunology 2004 173:3631-3639 PMID:15356107
- Redmond, W. L., Hernandez, J., Sherman, L. A. Deletion of naive CD8 T cells requires persistent antigen and is not programmed by an initial signal from the tolerogenic APC Journal of Immunology 2003 171:6349-6354 PMID:14662832
- Hernandez, J., Aung, S., Redmond, W. L., Sherman, L. A. Phenotypic and functional analysis of CD8(+) T cells undergoing peripheral deletion in response to cross-presentation of self-antigen Journal of Experimental Medicine 2001 194:707-717 DOI:10.1084/jem.194.6.707 PMID:11560988 PMCID:PMC2195957
- McKisic, M. D., Redmond, W. L., Barthold, S. W. T cell-mediated pathology in murine lyme borreliosis Journal of Immunology 2000 164:6096-6099 PMID:10843657